Attention!

What is the drug TENOFOVIR+EMTRICITABINE VM

TENOFOVIR+EMTRICITABINE VM is a combination drug with a fixed dose of emtricitabine and tenofovir disoproxil fumarate.

Emtricitabine is a nucleoside analog of cytidine. Tenofovir disoproxil fumarate is converted in vivo to the tenofovir nucleoside monophosphate (nucleotide) analog of adenosine monophosphate. Both emtricitabine and tenofovir show specific activity against the human immunodeficiency virus (HIV-1 and HIV-2) and hepatitis B virus (HBV).

Emtricitabine and tenofovir are phosphorylated by intracellular enzymes to form emtricitabine triphosphate and tenofovir diphosphate, respectively. In vitro studies have shown that both emtricitabine and tenofovir can be completely phosphorylated when they are simultaneously present in cells. Emtricitabine triphosphate and tenofovir diphosphate inhibit HIV-1 reverse transcriptase by a competitive mechanism, leading to termination of viral DNA chain synthesis. 

Dosage form

Oval biconvex tablets covered with a blue film coating. On a cross-section, the core is white or almost white in color.

Indications for use

Treatment of HIV-1 infection

- Treatment of HIV-1 infection in adults in combination therapy with other antiretroviral drugs.

- Treatment of HIV-1 infection in adolescents from 12 years of age who are resistant to нуклеозиднымnucleoside reverse transcriptase inhibitors, or who are not suitable for first-line treatment regimens due to toxicity.

Pre-exposure prophylaxis (PREP)

- In combination with safe sex methods for PREP to reduce the risk of sexual transmission of HIV-1 infection in adults at increased risk.

Efficacy and safety studies

In accordance with current legislation, the drug has proven its effectiveness, safety and quality during state registration. For registration purposes, a bioequivalence study was conducted with the original (reference) medicinal product.